TORONTO--(BUSINESS WIRE)-- OBIO is pleased to announce that Dr. Maura Campbell, Vice President, Intellectual Property and Contracts, Turnstone Biologics, was appointed as Chair of the OBIO Board of Directors.

“I am very pleased to have a leader of Maura’s calibre and experience as the Chair of the OBIO Board of Directors,” said Gail Garland, President and CEO, OBIO. “Maura is the first female Board Chair at OBIO and her depth of knowledge, her track record in the health science industry, and her energy all make her uniquely positioned to help guide OBIO as we continue to build the health science industry. Over the past 12 months, OBIO has launched the Early Adopter Health Network (EAHN™), published two industry-leading reports on the state of the health science industry including Leading the Pack: Accelerating the Success of the Canadian Health Science Industry, and held the 2021 OBIO Investment Summit which featured over 80 global investors and over 50 companies from across Canada.”

“I am honoured to join OBIO as the Chair of the Board of Directors,” said Dr. Maura Campbell. “I am excited to bring my experience in technology transfer and the management and commercialization of intellectual property to help further OBIO’s success,” said Dr. Campbell. “As a thought leading organization, OBIO’s work is truly building the health science industry and it is my privilege to be a part of OBIO’s efforts to support technology commercialization, workforce development and market acceleration in the health science industry.”

“I am grateful to have had the opportunity to serve as the Chair of the OBIO Board of Directors,” said Dr. Jeremy Bridge-Cook, Chief Scientific Officer and VP R&D, Spartan Bioscience, and outgoing OBIO Board Chair. “OBIO has done incredible work to support the growth of the health science industry in Canada. With the leadership and enthusiasm that Maura brings, I am confident that OBIO’s work will continue to drive even more success for health science companies. I look forward to what comes next.”

Dr. Maura Campbell – biography

Dr. Maura Campbell is Vice President, Intellectual Property and Contracts at Turnstone Biologics. Maura has spent more than 30 years in technology transfer and the management and commercialization of intellectual property (IP). She has business management experience in all key sectors of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations (National Centre of Excellence [NCE]).

Maura helped spin out Turnstone Biologics from IP developed at three Ontario academic institutes in 2015. Maura has had an active role in the Company’s Series A, B and C financing, raising a total of over $90 million (U.S.). Previously, Maura was with VBI Vaccines where she served as Director, Intellectual Property. Prior to this she was with the Ottawa Hospital Research Institute (OHRI) as a Senior Research Program Manager, where she oversaw the oncolytic vaccine project commercialization.

Earlier in her career, Maura was the Director of Intellectual Property for PainCeptor Pharma Corporation, the Manager of Technology Transfer & Commercialization for the OHRI, and the Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems NCE. She has also served as an IP consultant to a number of Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC and Sussex Research Labs.

Maura received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston.

About OBIO

The Ontario Bioscience Innovation Organization (OBIO^®) founded in 2009, is a not-for-profit, membership-based organization engaged in strategy, programming, policy development and advocacy to further the commercialization of Ontario’s human health technologies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, the health system and government.

For more information, please visit www.obio.ca and follow OBIO on Twitter @OBIOscience.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005258/en/